biostudies-literatureUnknown13Puliani GPeptide receptor radionuclide therapy (PRRT) using radiolabeled somatostatin analogs has been used for over two decades for the treatment of well-differentiated neuroendocrine tumors (NETs), and the publication of the NETTER-1 trials has further strengthened its clinical use. However, many aspects of this treatment are still under discussion. The purpose of this review is to collect and discuss the new available evidence, published in 2021, on the use of ¹⁷⁷Lu-Oxodotreotide (DOTATATE) or ⁹⁰Y-Edotreotide (DOTATOC) in adult patients with NETs focusing on the following hot topics: 1) PRRT use in new clinical settings, broaden its indications; 2) the short- and long-term safety; and 3) the identification of prognostic and predictive factors. The review suggests a possibleFrontiers in endocrinology861434https://www.ebi.ac.uk/biostudies/studies/S-EPMC9016202biostudies-literatureNew Insights in PRRT: Lessons From 2021.PMC9016202Mormando MPuliani GChiefari ABianchini MAppetecchia MLauretta RfalseNew Insights in PRRT: Lessons From 2021.Peptide receptor radionuclide therapy (PRRT) using radiolabeled somatostatin analogs has been used for over two decades for the treatment of well-differentiated neuroendocrine tumors (NETs), and the publication of the NETTER-1 trials has further strengthened its clinical use. However, many aspects of this treatment are still under discussion. The purpose of this review is to collect and discuss the new available evidence, published in 2021, on the use of ¹⁷⁷Lu-Oxodotreotide (DOTATATE) or ⁹⁰Y-Edotreotide (DOTATOC) in adult patients with NETs focusing on the following hot topics: 1) PRRT use in new clinical settings, broaden its indications; 2) the short- and long-term safety; and 3) the identification of prognostic and predictive factors. The review suggests a possible2022-01-01T00:00:00Z20222025-04-05T11:51:54.127Z2025-02-19T04:57:23.157ZS-EPMC90162023545042110.3389/fendo.2022.861434